Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Biomarker Research

Figure 2

From: Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

Figure 2

Kinetics of BCR-ABL1 expression. The black bars indicate the median. The gray bars indicate quartiles 1 and 3. The X-axis shows the time-point and patient number for evaluation of molecular responses. The Y-axis shows BCR-ABL1 transcript levels per the international scale of standardized quantitative real-time polymerase chain reaction.

Back to article page